#United States #Framingham #Pulmatrix #Cullgen #iSPERSE™

Pulmatrix's 2025 Financial Results and Merger Update

Pulmatrix, Inc., a biopharmaceutical company listed on Nasdaq under the symbol PULM, has released its financial results for the year ending December 31, 2025. The company focuses on developing innovative inhaled treatments for conditions such as migraines and respiratory diseases through its proprietary technology, iSPERSE™.

On February 26, 2026, Pulmatrix shared its year-end financial information along with significant updates on its merger with Cullgen, a private biopharmaceutical entity engaged in targeted therapies for pain, cancer, and other conditions.

Key Developments in the Fourth Quarter and Merger Plans

CEO Peter Ludlum emphasized the importance of progressing with the merger, stating that it has been a priority for Pulmatrix in the fourth quarter. On November 13, 2024, the companies entered a merger agreement, which has seen adjustments with the latest amendment on April 7, 2025. The merger hinges on regulatory approval from the China Securities Regulatory Commission (CSRC), along with additional conditions that involve coordination with Nasdaq regarding stock listings. Notably, both companies have agreed to waive the 'No Solicitation' clause in their merger agreement. This allows them to pursue alternate transactions beneficial to their respective interests while still working towards finalizing the merger with regulatory bodies.

Advances in iSPERSE™ Technology and Clinical Programs

Pulmatrix is concurrently exploring strategic partnerships to license its patent portfolio related to iSPERSE™ technology and its clinical programs, including a Phase 2 ready migraine treatment. iSPERSE™ represents a revolutionary approach, utilizing engineered particles designed for optimal inhalation therapy delivery, outperforming conventional methods.

Currently, Pulmatrix's portfolio includes several promising assets:
1. PUR3100 - A ready-to-move Phase 2 product for acute migraine treatment, now with an approved IND application, demonstrating favorable outcomes in initial studies published in notable medical journals.
2. PUR1800 - A kinase inhibitor for treating acute exacerbations in chronic obstructive pulmonary disease (COPD), showing a strong safety profile from Phase 1b studies.
3. PUR1900 - An inhaled formulation containing itraconazole, approved to advance into Phase 3 trials in India by its manufacturing partner, Cipla. This project follows assessments that indicated the feasibility of PUR1900 for various medical applications.

Financial Overview

In terms of financial health, Pulmatrix reported zero revenues for the 2025 fiscal year, a decline from $7.8 million in 2024, a shift largely due to the conclusion of the PUR1900 agreement activities. The research and development expenses dropped significantly, falling from $7.2 million in 2024 to under $0.1 million in 2025, primarily due to winding down costs related to clinical trials. Despite the declines, administrative costs also reflected savings, resulting from reduced operational activities connected to the merger and clinical trial activities.

Interestingly, as of December 31, 2025, the company's cash reserves totaled $4.1 million, down from $9.5 million the previous year. Pulmatrix anticipates its financial position will be adequate to sustain operations through the first quarter of 2027, although careful management and prioritization of expenses will be critical going forward.

Conclusion and Future Outlook

These developments demonstrate Pulmatrix's ongoing dedication to enhancing treatment avenues for patients through innovative therapies founded on iSPERSE™. The successful merger with Cullgen and strategic licensing opportunities will be pivotal as the company seeks to navigate these challenging financial waters while maintaining a commitment to medical advancement in under-served areas of health.

As Pulmatrix continues to push forward with its strategic initiatives, stakeholders will closely monitor the progress on both the merger and the development of its clinical assets in 2026.

About Pulmatrix

Pulmatrix, Inc. is dedicated to developing cutting-edge inhaled therapeutic products aimed at addressing critical unmet medical needs in migraine and respiratory disease treatment through its proprietary iSPERSE™ technology. The company aims to revolutionize drug delivery methods and patient outcomes by enhancing the therapeutic potential of inhalable medications.

For further details on Pulmatrix’s pipeline and developments, visit their official website at Pulmatrix.com.